Predicting Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric and Gastroesophageal Junction Cancer Using Multi-Omics Data

What this Trial Is About

Researchers are studying advanced gastric and gastroesophageal junction cancer in patients who are undergoing immunotherapy combined with chemotherapy. This project focuses on collecting and analyzing detailed multi-omics data to find key features linked to how well immunotherapy works. The study aims to identify potential molecular markers and dominant microbiota that could predict treatment effects and help improve therapy decisions for these advanced cancers. Participants will receive chemotherapy combined with immunotherapy as part of their treatment. Samples such as peripheral blood, tongue coating, saliva, and feces will be collected along with clinical data from these patients. This observational study will monitor patients over time to develop and validate a model that predicts response to the combined therapy. During the study, researchers will assess tumor response and overall survival over periods up to 60 months. Progression-free survival will also be evaluated. Patients will undergo regular evaluations to track treatment effects and disease progression. The study will provide insights to help predict which patients may benefit most from immunotherapy combined with chemotherapy, supporting optimized treatment planning.

Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.